Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment

Immunocompromised patients are at increased risk for a severe course of COVID-19. Treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with anti-SARS-CoV-2 monoclonal antibodies (mAbs) has become widely accepted. However, the effects of mAb treatment on the long-term p...

Descripción completa

Detalles Bibliográficos
Autores principales: Thümmler, Laura, Konik, Margarethe, Lindemann, Monika, Fisenkci, Neslinur, Koldehoff, Michael, Gäckler, Anja, Horn, Peter A., Theodoropoulos, Fotis, Taube, Christian, Zettler, Markus, Anastasiou, Olympia Evdoxia, Braß, Peer, Jansen, Sarah, Witzke, Oliver, Rohn, Hana, Krawczyk, Adalbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606643/
https://www.ncbi.nlm.nih.gov/pubmed/36311723
http://dx.doi.org/10.3389/fimmu.2022.980698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606643/
https://www.ncbi.nlm.nih.gov/pubmed/36311723
http://dx.doi.org/10.3389/fimmu.2022.980698

Ejemplares similares